|
Synonyms: Aerumab 11 | Aerumab™ | AR-101 | KBPA101
Compound class:
Antibody
Comment: Panobacumab is a fully human IgM kappa monoclonal antibody directed against the O-polysaccharide component of surface lipopolysaccharide (LPS) of serotype O11 Pseudomonas aeruginosa [1]. It is under clinical development as an adjunctive immunotherapy for the treatment of nosocomial pneumonia caused by O11 serotype P. aeruginosa.
Annotated peptide sequences for this monoclonal antibody are available from its IMGT/mAb-DB record. |
| No information available. |
Summary of Clinical Use  |
| In 2006, panobacumab was granted orphan designation by both the FDA and EMA for the treatment of hospital acquired pneumonia caused by serotype O11 P. aeruginosa. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT00851435 | Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa | Phase 1/Phase 2 Interventional | Kenta Biotech Ltd | 2-3 | |
